Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Felbamate in epilepsy therapy: evaluating the risks.

J M Pellock1

  • 1Division of Child Neurology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA. JPELLOCK@HSC.VCU.EDU

Drug Safety
|September 16, 1999
PubMed
Summary

Felbamate is an effective anticonvulsant for difficult-to-treat epilepsy. Careful patient monitoring and risk factor evaluation are crucial to minimize potential aplastic anemia and liver failure risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Evaluation of Medial Temporal Lobe Morphology in Children with Febrile Status Epilepticus: Results of the FEBSTAT Study.

AJNR. American journal of neuroradiology·2016
Same author

Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations.

Acta neurologica Scandinavica. Supplementum·2011
Same author

Balancing clinical benefits of vigabatrin with its associated risk of vision loss.

Acta neurologica Scandinavica. Supplementum·2011
Same author

The occurrence and characteristics of auras in a large epilepsy cohort.

Acta neurologica Scandinavica·2008
Same author

Phenomenology of prolonged febrile seizures: results of the FEBSTAT study.

Neurology·2008
Same author

New developments in the treatment of epilepsy.

CNS spectrums·2008

Area of Science:

  • Pharmacology
  • Neurology
  • Toxicology

Background:

  • Felbamate offers unique seizure control when other treatments fail.
  • Its use is linked to serious risks like aplastic anemia and hepatic failure.
  • Confounding factors complicate the exact incidence rates of these adverse effects.

Purpose of the Study:

  • To identify risk factors and clinical profiles associated with felbamate-induced aplastic anemia and hepatic failure.
  • To provide guidance on minimizing toxicity risks through monitoring and patient education.

Main Methods:

  • Review of reported cases of aplastic anemia and hepatic failure associated with felbamate.
  • Analysis of patient demographics, concomitant medications, and medical history.
  • Exploration of potential biochemical markers for toxicity.

Main Results:

  • Aplastic anemia risk factors include female gender, Caucasian ethnicity, adult age, history of anticonvulsant allergy/toxicity, prior cytopenia, and immune disorders.
  • Hepatic failure demographics are less defined but also predominantly female; concomitant medications like valproic acid are frequent.
  • In 50% of hepatic failure cases, confounding factors other than felbamate were implicated.

Conclusions:

  • Felbamate remains a valuable anticonvulsant, but risks necessitate careful evaluation before treatment.
  • Pre-therapy laboratory tests (liver function, CBC) and ongoing monitoring are essential.
  • Patient education on prodromal toxicity symptoms is vital for safe felbamate use.

Related Experiment Videos